(415) 353-9888 (appts)
(415) 353-7023 (fax)

Box 1705, UCSF; San Francisco, CA 94143-1705

additional websites:

UCSF Physician Referral Directory
Korn Lab Website

Philipps University of Marburg, Germany, Continuing Education, 1981 - 1984, Medicine
Heinrich-Heine University of Düsseldorf, Germany, Approbation as Physician, 1984 - 1988, Medicine
Philipps University of Marburg, Germany, Medical Doctorate, 1993
University of Bern, Switzerland, Internship, 1997, Medicine

Korn, M.W., Olde Weghuis, D.E.M., Suijkerbuijk, R.F., Schmidt, U., Otto, T., du Manoir, S., Geurts van Kessel, A., Harstrick, A., Seeber, S., Becher, R., Detection of chromosomal DNA gains and losses in testicular germ cell tumors by Comparative Genomic Hybridization.Genes Chromosom. Cancer 1996, 17:78-87

Klaassen, U., Wilke, H., Strumberg, D., Eberhardt, W., Korn, M., Seeber, S., Phase I Study with weekly 1h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Eur. J. Cancer 1996, 32A:547-549

Wilke, H., Korn, M., Vanhofer, U., Fink, U., Stahl, M., Preusser, P., Kohne, C., Klassen, U., Harstrick, A., Schmoll, H.J., Seeber, S., Weekly infusional 5-fluorouracil plus/minus other drugs for the treatment of advanced gastric cancer. J. Infus. Chemother. 1996; 6:123-126

Harstrick A., Wilke H., Eberhardt W., Klaassen U., Strumberg D., Korn M., Scheulen M.E., Baumgart J., Seeber S., A phase I dose escalation trial of intravenous treosulfan in refractory cancer. Onkologie 1996; 19: 153-156

Stahl M., Vanhoefer U., Fink U., Korn M., Eigler F.W., Siewert J.R., Seeber S., Wilke H., Phase II study of weekly high-dose 5-fluorouracil and folinic acid plus biweekly alternating cisplatin and epirubicin (FUFACE) in patients with advanced gastric carcinoma. Onkologie 1996; 19: 416-418

Strumberg, D., Harstrick, A., Klaassen, U., Muller C., Eberhardt, W., Korn, M.W., Wilke, H., Seeber, S., Phase II trial of continuous oral trofosfamide in patients with advanced colorectal cancer refractory to 5-fluorouracil. Anticancer Drugs 1997, 8: 293-295

Becher, R., Korn, W.M., Prescher, G., Use of fluorescence in situ hybridization and comparative genomic hybridization in the cytogenetic analysis of testicular germ cell tumors and uveal melanomas. Cancer Genet. Cytogenet. 1997, 93: 22-28

Klaassen, U., Wilke, H., Muller, C., Borquez, D., Korn, M., Achterrath, W., Harstrick, A., Diergarten, K., Seeber, S., Infusional 5-FU, folinic acid, paclitaxel, and cisplatin for metastatic breast cancer. Oncology 1997, 11 (Suppl 3): 38-40

Klaassen, U., Wilke, H., Weyhofen, R., Harstrick, A., Eberhardt, W., Muller, C., Korn, M., Hanske, M., Diergarten, K., Seeber, S. Phase II study with cisplatin and paclitaxel in combination with weekly high-dose 24 h infusional 5-fluorouracil/leucovorin for first-line treatment of metastatic breast cancer. Anticancer Drugs. 1998 Mar;9:203-7.

Korn, W.M., Yasutake, T., Kuo, W.-L., Warren, R.S., Collins, C., Tomita, M., Gray, J., Waldman, F.M., Chromosome 20q gains and other genomic copy number changes in metastatic colorectal cancer analyzed by comparative genomic hybridization and fluorescence in situ hybridization. Genes Chromosom. Cancer 1999, 25: 82-90

Ries, S.J., Brandts, C.H., Chung, A.S., Biederer, C.H., Hann, B.C., Lipner, E.M. McCormick, F., Korn, W.M., Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat. Med., 2000, 6: 1128-1133

Yount, G.L., Afshar, G., Ries, S., Korn, M., Shalev, N., Aldape, K.D., McCormick, F., Haas-Kogan, D.A., Transcriptional Activation of TRADD mediates p53-independent radiation-induced apoptosis in glioma cells. Oncogene 2001, 20, 2826-2835

Ries, S., Korn, W.M., ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus. Br. J. Cancer. 2002, 86:5-11

Strumberg, D., Brugge, S., Korn, M.W., Koeppen, S., Ranft, J., Scheiber, G., Reiners, C., Mockel, C., Seeber, S., Scheulen, M.E., Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann. Oncol. 2002,13:229-36

Anders, M., Hansen, R., Ding, R.-X. Rauen, K.A., Bissell, M.J., Korn, W.M., Disruption of three-dimensional tissue integrity facilitates adenovirus infection by deregulating the Coxsackievirus and Adenovirus Receptor. PNAS, 2003, 100:1943-48

Anders, M., Christian, C., McMahon, M., McCormick, F, and Korn, W.M., Inhibition of the Raf-MEK-ERK pathway upregulates expression of the Coxsackievirus and Adenovirus Receptor in cancer cells. Cancer Res 2003, 63: 2088 - 2095

Korn, W.M., Prevention and Management of Early Esophageal Cancer. Current Treatment Options in Oncology, 2004, 5: 405-416

Au, T., Thorne, S., Korn, W.M., Sze, D., Kirn, D., and Reid, T.R. Minimal hepatic toxicity pf ONYX-015: spatial restriction of CAR receptor in normal liver. Cancer Gene Therapy, 2006; [Epub ahead of print]

Korn, W.M., Macal, M., Christian, C., Ding, R.-X., Rauen, K.A., Warren, R.S., and Ferrell, L., Expression of the Coxsackievirus and Adenovirus Receptor in gastrointestinal tumors correlates with tumor differentiation. Cancer Gene Therapy, 2006; 13:792-7

Lacher, M., Anders, M., Oft, M., Balmain, A., Korn, W.M., TGF receptor inhibition enhances adenoviral infectivity of carcinoma cells via up-regulation of CAR consequent to mesenchymal-epithelial-transition. Cancer Research, Cancer Res. 2006;66:1648-57

Au, T., Thorne, S., Korn, W.M., Sze, D., Kirn, D., and Reid, T.R. Minimal hepatic toxicity pf ONYX-015: spatial restriction of CAR receptor in normal liver. Cancer Gene Therapy, 2007, 14: 139-150

Lu, D., Theodore, P., Korn, W.M., Chou, D., Esophageal Erosion Nine Years After Anterior Cervical Plate Implantation. Surgical Neurology, Surgical Neurology, 2008, 69: 310-312

Mirzoeva, O.K., Das, D., Heiser, L.M., Bhattacharya, S., Siwak, D., Gendelman, R., Bayani, N., Wang, N.J., Neve, R.M., Parvin, P., Knight, Z., Feiler, H.S., Gascard, P., Spellman, P.T., Shokat, K.M., Wyrobek, A., Bissell, M.J., McCormick, F., Kuo, W.-L., Mills, G.M., Gray, J.W., Korn, W.M., Basal-subtype and MEK-PI3K feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Research, 2009, 69: 565-572

Chapters

Korn, W.M., Becher, R. Bedeutung klinischer Studien für Fortschritte in der palliativen Krebstherapie [Relevance of clinical studies for advances in palliative cancer treatment]. Zuckschwerdt Vlg., München, Bern, Wien, New York, 1996, 18-45

Patti MG, Galvani C, Korn WM. Benign and malignant disorders of the esophagus. In: Current Diagnosis and Treatment in Otolaryngology - Head and neck surgery. Appleton & Lange, New York, 2004, 509 - 524

SELECTED ABSTRACTS

Korn, W.M., Speicher, M.R., Zhang, X.D., Otto, T., Rübben, H., Schmidt, U., Leder, L.D., Cremer, T., Seeber, S., Becher, R., Cytogenetic and molecular cytogenetic analysis of testicular germ cell tumors using comparative genomic hybridization with DNA from fresh tumors and paraffin embedded fixed tumor sections. Proc. Am. Assoc. Cancer Res. 1994, 35:196

Koeppen, S., Korn, W.M., Brugge, S., Schmitz, D., Scheulen, M.E., Long-term neurotoxicity after testicular cancer chemotherapy. J. neurology 1994, 241, Suppl. 1, 61

Korn, W.M., Harstrick, A., Prescher, G., Du Manoir, S., Wilke, H.J., Seeber, S. & Becher, R., Comparative genomic hybridization and conventional cytogenetic analysis of three newly established stomach cancer cell lines. Second international conference on biology, prevention and treatment of gastrointestinal malignancies. Köln, Germany, 1995

Vanhoefer, U., Wilke, H,., Fink, U., Köhne-Wömpner, C., Preusser, P., Korn, W.M., Stahl, M., Achterrath, W., Harstrick, A., Klaassen, U., Schmoll, H.J., Seeber, S. Weekly 24h-Infusion of high-dose FU (HD-FU) plus folinic acid (FA) plus biweekly cisplatin (C) = (group A) or HD-FU/FA/C plus epirubicin (E) = (group B) in locally advanced (LAD) or metastatic advanced gastric cancer (GC). Proc. Am. Assos. Clin. Oncol. 1995, 14:464

Korn, W.M., Du Manoir, S., Otto, T., Schmidt, U., Seeber, S., & Becher, R., Conventional and molecular cytogenetic analysis of testicular germ cell tumors. Eur. J. Cancer 1995, 31; Suppl. 3, 901

Klaassen, U., Wilke, H., Müller, C., Borquez, D., Korn, W.M., Harstrick, A., Diergarten, K., Onetto, N., Seeber, S., Weekly high-dose 24-hour infusional 5-FU plus leucovorin (HD5-FD-LV) in combination with paclitaxel (P) and cisplatin (C) in the first-line treatment of metastatic breast cancer (MBC): results of a phase II study. Proc. Am. Assos. Clin. Oncol. 1997, 16, 618

Korn, W.M., Kuo, W.-L., Warren, R.S., Collins, C., Yasutake, T., Gray, J., Waldman, F.M., Characterization of copy number increases of chromosome 20q sequences in hepatic metastases of colorectal cancer by Fluorescense in situ Hybridization (FISH) Proc. Proc. Am. Assoc. Cancer Res. 1998, 39, 346

Anders, M., Ding, R. X., Lipner, E. M., Balmain, A., McCormick, F., Korn, W.M., Inhibition of the MAPK pathway up-regulates the human Coxsackie and Adenovirus Receptor (CAR) and increases the infectivity of cancer cells with adenoviruses. Proc. Am. Assoc. Cancer Res. 2001, 42, 703

Korn, W.M., Anders, M., Ding, R.-X., Christian, C., Hann, B., and Warren, R.S., Correlation of Histological Grade and Expression Patterns of the Coxsackie and Adenovirus Receptor (CAR) in Normal Liver Tissue and Malignant Liver Tumors. Proc. Am. Assoc. Cancer Res. 2002, 43, 3980

Anders, M., Oft, M., Balmain, A., Korn, W.M., Cooperative Regulation of the Coxsackie and Adenovirus Receptor (CAR) by Ras and TGF in Cancer Cells. Proc. Am. Assoc. Cancer Res. 2003, 44, 2800

Lacher, M., Anders, M., and Korn, W.M., Regulation of the coxsackievirus and adenovirus receptor (CAR) during epithelial-to-mesenchymal transition (EMT). Proc. Am. Assoc. Cancer Res. 2004, 45, 4592

Lacher, M.D., Tiirikainen, M.I., Christian, C.M., Saunier, E.F., Balmain, A., Akhurst, R.J., Korn, W.M., Restoration of expression of the Coxsackie and Adenovirus Receptor (CAR) in pancreatic cancer cells through pharmacological inhibition of TGFβ signal transduction. Proc. Am. Assoc. Cancer Res. 2005, 46, 5031

Zhang, J., Yiling Lu, Y., Christian, C., Mirzoeva, O., Mills, G., Korn, W.M., Molecular and cellular responses ot EGFR inhibition in esophageal adenocarcinoma cells. Am. Assoc. Cancer Res. 2006, 47, 4670

1/12/09